These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 35323364)

  • 21. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis.
    O'Reilly MA; Wilson W; Burns D; Kuhnl A; Seymour F; Uttenthal B; Besley C; Alajangi R; Creasey T; Paneesha S; Elliot J; Gonzalez Arias C; Iyengar S; Wilson MR; Delaney A; Rubio L; Lambert J; Begg K; Boyle S; Cheok KPL; Collins GP; Roddie C; Johnson R; Sanderson R
    Hemasphere; 2024 Jun; 8(6):e87. PubMed ID: 38873532
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P; Simpson E; Hamilton J; Pollard D; Clowes M; Kaltenthaler E; Meiklejohn D; Morley N
    Pharmacoeconomics; 2019 Mar; 37(3):333-343. PubMed ID: 30246228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
    Ito D; Feng C; Fu C; Kim C; Wu J; Epstein J; Snider JT; DuVall AS
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):773-787. PubMed ID: 37278284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis.
    J Wu J; Wade SW; Itani T; Castaigne JG; Kloos I; Peng W; Kanters S; Zoratti MJ; Dreyling M; Shah B; Wang M
    Leuk Lymphoma; 2024 Jul; ():1-14. PubMed ID: 38975903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
    Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
    J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions.
    Bond DA; Martin P; Maddocks KJ
    J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33799484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States.
    Roth JA; Sullivan SD; Lin VW; Bansal A; Purdum AG; Navale L; Cheng P; Ramsey SD
    J Med Econ; 2018 Dec; 21(12):1238-1245. PubMed ID: 30260711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Effectiveness Analysis of Relmacabtagene Autoleucel for Relapsed or Refractory Large B-Cell Lymphoma in China.
    Lin Z; Zuo C; Jiang Y; Su W; Yao X; Man Y; Wu Q; Xuan J
    Value Health Reg Issues; 2023 Sep; 37():41-48. PubMed ID: 37209540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma.
    Mohty R; Kharfan-Dabaja MA
    Ther Adv Hematol; 2022; 13():20406207221142133. PubMed ID: 36544864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pirtobrutinib: A novel non-covalent BTK inhibitor for the treatment of adults with relapsed/refractory mantle cell lymphoma.
    Davis DD; Ohana Z; Pham HM
    J Oncol Pharm Pract; 2024 Jan; 30(1):182-188. PubMed ID: 38043933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL.
    Rejeski K; Wang Y; Albanyan O; Munoz J; Sesques P; Iacoboni G; Lopez-Corral L; Ries I; Bücklein VL; Mohty R; Dreyling M; Baluch A; Shah B; Locke FL; Hess G; Barba P; Bachy E; Lin Y; Subklewe M; Jain MD
    Am J Hematol; 2023 Nov; 98(11):1699-1710. PubMed ID: 37584447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
    Beitinjaneh A; Kaufman A; Wang Y; Jain P; Srour SA; Wang M
    Curr Treat Options Oncol; 2022 Nov; 23(11):1614-1625. PubMed ID: 36227407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma.
    Li P; Dong N; Zeng Y; Liu J; Tang X; Wang J; Zhang W; Ye S; Zhou L; Chang AH; Liang A
    Front Med; 2020 Dec; 14(6):811-815. PubMed ID: 32651937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
    Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J
    Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy.
    Jain P; Nastoupil L; Westin J; Lee HJ; Navsaria L; Steiner RE; Ahmed S; Moghrabi O; Oriabure O; Chen W; Badillo M; Flowers CR; Wang ML
    Br J Haematol; 2021 Jan; 192(2):e38-e42. PubMed ID: 33152104
    [No Abstract]   [Full Text] [Related]  

  • 36. SOHO State of the Art Updates and Next Questions: Managing Relapsed Mantle Cell Lymphoma.
    Romancik JT; Gerber DG; Zhuang T; Cohen JB
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):557-565. PubMed ID: 35123927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France.
    Karampampa K; Zhang W; Venkatachalam M; Cotte FE; Dhanda D
    J Med Econ; 2023; 26(1):243-253. PubMed ID: 36705644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.
    Bouchkouj N; Lin X; Wang X; Przepiorka D; Xu Z; Purohit-Sheth T; Theoret M
    Oncologist; 2022 Oct; 27(10):892-899. PubMed ID: 35983953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
    Wang M; Munoz J; Goy A; Locke FL; Jacobson CA; Hill BT; Timmerman JM; Holmes H; Jaglowski S; Flinn IW; McSweeney PA; Miklos DB; Pagel JM; Kersten MJ; Milpied N; Fung H; Topp MS; Houot R; Beitinjaneh A; Peng W; Zheng L; Rossi JM; Jain RK; Rao AV; Reagan PM
    N Engl J Med; 2020 Apr; 382(14):1331-1342. PubMed ID: 32242358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma.
    Potnis KC; Di M; Isufi I; Gowda L; Seropian SE; Foss FM; Forman HP; Huntington SF
    Blood Adv; 2023 Mar; 7(5):801-810. PubMed ID: 36342852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.